Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDAKNASDAQ:CDAKQNYSE:LCINNASDAQ:TCBP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDAKCodiak BioSciences$0.00$0.00$0.05▼$6.98$59K3.711.37 million shsN/ACDAKQCodiak BioSciences$0.00$0.00$0.00▼$3.26$59K3.43905,289 shsN/ALCINLannett$0.02$0.01▼$0.02$160K0.92475,780 shs441,200 shsTCBPTC Biopharm$0.68-55.8%$0.68$0.50▼$160.00$279K0.01157,979 shs5.33 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDAKCodiak BioSciences0.00%0.00%0.00%0.00%0.00%CDAKQCodiak BioSciences0.00%0.00%0.00%0.00%0.00%LCINLannett0.00%0.00%0.00%0.00%0.00%TCBPTC Biopharm0.00%0.00%0.00%+36.20%-99.55%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDAKCodiak BioSciences0.7085 of 5 stars0.00.00.04.60.01.70.6CDAKQCodiak BioSciencesN/AN/AN/AN/AN/AN/AN/AN/ALCINLannettN/AN/AN/AN/AN/AN/AN/AN/ATCBPTC Biopharm1.4895 of 5 stars3.50.00.00.00.70.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDAKCodiak BioSciences 0.00N/AN/AN/ACDAKQCodiak BioSciences 0.00N/AN/AN/ALCINLannett 0.00N/AN/AN/ATCBPTC Biopharm 3.00Buy$48.006,948.46% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDAKCodiak BioSciences$33.57M0.00N/AN/A$2.39 per share0.00CDAKQCodiak BioSciences$22.93M0.00N/AN/A$2.39 per share0.00LCINLannett$340.58M0.00N/AN/A($23.34) per share0.00TCBPTC Biopharm$4.76M0.06N/AN/A$519.58 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDAKCodiak BioSciences-$37.16M-$0.69N/A∞N/A-51.13%-109.51%-34.44%N/ACDAKQCodiak BioSciences-$37.16M-$0.69N/A∞N/AN/AN/AN/AN/ALCINLannett-$231.62M-$18.88N/AN/AN/A-62.40%N/A-13.39%N/ATCBPTC Biopharm-$7.35MN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDAKCodiak BioSciencesN/AN/AN/AN/AN/ACDAKQCodiak BioSciencesN/AN/AN/AN/AN/ALCINLannettN/AN/AN/AN/AN/ATCBPTC BiopharmN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDAKCodiak BioSciences0.664.244.24CDAKQCodiak BioSciencesN/AN/AN/ALCINLannettN/A2.231.39TCBPTC Biopharm0.671.12N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDAKCodiak BioSciences71.30%CDAKQCodiak BioSciences25.32%LCINLannett40.28%TCBPTC Biopharm16.25%Insider OwnershipCompanyInsider OwnershipCDAKCodiak BioSciences8.20%CDAKQCodiak BioSciences8.20%LCINLannett13.12%TCBPTC Biopharm15.44%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDAKCodiak BioSciences10236.83 million33.81 millionNot OptionableCDAKQCodiak BioSciences10236.83 million33.81 millionOptionableLCINLannettN/A10.49 million9.35 millionOptionableTCBPTC Biopharm80410,00028,000Not OptionableCDAK, CDAKQ, TCBP, and LCIN HeadlinesRecent News About These CompaniesTC Biopharm (NASDAQ:TCBP) versus Fate Therapeutics (NASDAQ:FATE) Critical ReviewJune 14, 2025 | americanbankingnews.comTC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) PatientJune 11, 2025 | prnewswire.comTC BioPharm Holdings PLC (TCBPY)May 11, 2025 | investing.comTCBP Announces Grant of European Patent for Targeting of Microbial, Oncological, and Viral Indications using Modified Gamma Delta T CellsApril 9, 2025 | finance.yahoo.comTC BioPharm: TCBP Announces Transition from Nasdaq to OTC MarketsMarch 24, 2025 | finanznachrichten.deTC BioPharm to be delisted from Nasdaq, moves to OTC MarketsMarch 23, 2025 | uk.investing.comTC Biopharm announces transition to OTC Markets from NasdaqMarch 22, 2025 | markets.businessinsider.comTC BioPharm Stock Crashes On Nasdaq Delisting: Retail Expresses FrustrationMarch 21, 2025 | msn.comTC BioPharm Transitions from Nasdaq to OTC Markets Amid Delisting NoticeMarch 21, 2025 | tipranks.comTCBP Announces Transition from Nasdaq to OTC MarketsMarch 21, 2025 | prnewswire.comTC Biopharm launches cost reduction initiativesMarch 19, 2025 | finance.yahoo.comTCBP Announces Outsourcing Initiatives, Reducing Burn Rate and OverheadMarch 18, 2025 | prnewswire.comTC BioPharm: TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical CompanyMarch 5, 2025 | finanznachrichten.deTCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical CompanyMarch 5, 2025 | prnewswire.comEuropean Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for WeekFebruary 28, 2025 | msn.comTCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO ForumFebruary 20, 2025 | prnewswire.comTC BioPharm: TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical TrialFebruary 13, 2025 | finanznachrichten.deTCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical TrialFebruary 13, 2025 | prnewswire.comTC BioPharm: TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical TrialFebruary 11, 2025 | finanznachrichten.deTC Falls Despite Cohort B TrialsFebruary 11, 2025 | baystreet.caNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCDAK, CDAKQ, TCBP, and LCIN Company DescriptionsCodiak BioSciences NASDAQ:CDAKCodiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Codiak BioSciences NASDAQ:CDAKQCodiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. On March 27, 2023, Codiak BioSciences, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.Lannett NYSE:LCINLannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA.TC Biopharm NASDAQ:TCBP$0.68 -0.86 (-55.78%) Closing price 03/21/2025Extended Trading$0.68 0.00 (0.00%) As of 03/21/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
